Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Burkitt lymphoma in the mouse.

Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd.

J Exp Med. 2000 Oct 16;192(8):1183-90.

2.

The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.

Truffinet V, Pinaud E, Cogné N, Petit B, Guglielmi L, Cogné M, Denizot Y.

J Immunol. 2007 Nov 1;179(9):6033-42.

3.

Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.

Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.

Cancer Res. 1989 Jun 15;49(12):3235-41.

4.

Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells.

Zhu D, Qi CF, Morse HC 3rd, Janz S, Stevenson FK.

Blood. 2005 Mar 1;105(5):2135-7. Epub 2004 Nov 2.

5.

Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.

Vincent C, Truffinet V, Fiancette R, Petit B, Cogné N, Cogné M, Denizot Y.

Biochim Biophys Acta. 2009 Feb;1793(2):418-26. doi: 10.1016/j.bbamcr.2008.10.011. Epub 2008 Nov 3.

6.

Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.

Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S.

Cancer Res. 2005 Feb 15;65(4):1306-15.

7.
8.

Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.

Gerbitz A, Mautner J, Geltinger C, Hörtnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A, Bornkamm GW.

Oncogene. 1999 Mar 4;18(9):1745-53.

9.

Forward and reverse changes in Ig/myc translocation carrying tumors.

Klein G.

Princess Takamatsu Symp. 1989;20:135-42.

PMID:
2562178
11.

Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ.

Am J Surg Pathol. 2005 Dec;29(12):1652-60.

PMID:
16327438
13.
14.

c-MYC impairs immunogenicity of human B cells.

Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.

Adv Cancer Res. 2007;97:167-88. Review.

PMID:
17419945
15.
16.

A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.

Vincent-Fabert C, Fiancette R, Rouaud P, Baudet C, Truffinet V, Magnone V, Guillaudeau A, Cogné M, Dubus P, Denizot Y.

Am J Pathol. 2012 Apr;180(4):1688-701. doi: 10.1016/j.ajpath.2012.01.004. Epub 2012 Feb 9.

PMID:
22326754
17.

Myc suppression of Nfkb2 accelerates lymphomagenesis.

Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL.

BMC Cancer. 2010 Jul 2;10:348. doi: 10.1186/1471-2407-10-348.

18.

Biology of the lymphomas: cytogenetics, molecular biology, and virology.

Ambinder RF, Griffin CA.

Curr Opin Oncol. 1991 Oct;3(5):806-12. Review.

PMID:
1661167
19.

Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations.

Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse HC 3rd, Janz S.

Oncogene. 2002 Oct 17;21(47):7235-40.

20.

Id2 is dispensable for myc-induced lymphomagenesis.

Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL.

Cancer Res. 2004 Oct 15;64(20):7296-301.

Supplemental Content

Support Center